| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 33 | 2024 | 2141 | 4.160 |
Why?
|
| Heart Transplantation | 23 | 2023 | 827 | 1.740 |
Why?
|
| Heart-Assist Devices | 21 | 2025 | 1016 | 1.710 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 30 | 1.280 |
Why?
|
| Diuretics | 4 | 2022 | 136 | 1.020 |
Why?
|
| Water-Electrolyte Imbalance | 3 | 2023 | 77 | 1.010 |
Why?
|
| Cardiomyopathies | 8 | 2023 | 485 | 0.920 |
Why?
|
| Child | 59 | 2025 | 25038 | 0.900 |
Why?
|
| Hospitalization | 7 | 2024 | 1799 | 0.880 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2022 | 26 | 0.880 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2021 | 136 | 0.870 |
Why?
|
| Shock, Cardiogenic | 3 | 2024 | 169 | 0.820 |
Why?
|
| Heart Defects, Congenital | 7 | 2023 | 1832 | 0.790 |
Why?
|
| Renal Insufficiency | 3 | 2018 | 229 | 0.770 |
Why?
|
| Hyponatremia | 2 | 2023 | 70 | 0.650 |
Why?
|
| Retrospective Studies | 39 | 2024 | 16569 | 0.630 |
Why?
|
| Infant | 29 | 2025 | 12733 | 0.600 |
Why?
|
| Child, Preschool | 32 | 2025 | 14341 | 0.590 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 26 | 0.580 |
Why?
|
| Creatinine | 2 | 2018 | 359 | 0.580 |
Why?
|
| Hospital Mortality | 7 | 2024 | 960 | 0.570 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2019 | 655 | 0.530 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 492 | 0.530 |
Why?
|
| Acute Kidney Injury | 6 | 2025 | 597 | 0.530 |
Why?
|
| Cardiotonic Agents | 4 | 2019 | 132 | 0.530 |
Why?
|
| Adolescent | 35 | 2025 | 19921 | 0.500 |
Why?
|
| Anemia | 2 | 2018 | 329 | 0.490 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2019 | 275 | 0.470 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2014 | 349 | 0.460 |
Why?
|
| Humans | 70 | 2025 | 124973 | 0.460 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 77 | 0.440 |
Why?
|
| Mortality | 1 | 2016 | 244 | 0.440 |
Why?
|
| Hospitals, Pediatric | 7 | 2018 | 773 | 0.440 |
Why?
|
| Male | 49 | 2025 | 61670 | 0.430 |
Why?
|
| Female | 47 | 2025 | 67493 | 0.410 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2014 | 268 | 0.350 |
Why?
|
| Treatment Outcome | 21 | 2025 | 12233 | 0.340 |
Why?
|
| Graft Rejection | 10 | 2023 | 542 | 0.340 |
Why?
|
| Cohort Studies | 12 | 2021 | 4852 | 0.330 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2025 | 153 | 0.330 |
Why?
|
| Risk Factors | 12 | 2024 | 10275 | 0.310 |
Why?
|
| Acute Disease | 5 | 2023 | 1033 | 0.310 |
Why?
|
| Prognosis | 8 | 2023 | 4629 | 0.310 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 729 | 0.310 |
Why?
|
| Registries | 6 | 2025 | 1462 | 0.300 |
Why?
|
| Cardiology | 1 | 2014 | 470 | 0.300 |
Why?
|
| Infant, Newborn | 13 | 2021 | 8324 | 0.280 |
Why?
|
| Time Factors | 9 | 2020 | 5987 | 0.280 |
Why?
|
| Heart Arrest | 2 | 2014 | 357 | 0.280 |
Why?
|
| Young Adult | 10 | 2023 | 9535 | 0.280 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 23 | 0.270 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 244 | 0.250 |
Why?
|
| Heart Rate | 3 | 2025 | 563 | 0.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 196 | 0.250 |
Why?
|
| Electrocardiography | 3 | 2025 | 916 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 207 | 0.250 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 77 | 0.250 |
Why?
|
| Hemodynamics | 3 | 2025 | 800 | 0.240 |
Why?
|
| Milrinone | 1 | 2006 | 30 | 0.240 |
Why?
|
| Incidence | 6 | 2018 | 3157 | 0.240 |
Why?
|
| Pediatrics | 2 | 2019 | 1206 | 0.240 |
Why?
|
| Critical Illness | 4 | 2025 | 598 | 0.230 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2025 | 22 | 0.230 |
Why?
|
| Hemodynamic Monitoring | 1 | 2025 | 16 | 0.230 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 183 | 0.230 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 735 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2020 | 3389 | 0.230 |
Why?
|
| Adult | 12 | 2024 | 30051 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2020 | 381 | 0.220 |
Why?
|
| Dopamine | 1 | 2006 | 247 | 0.220 |
Why?
|
| Sodium | 2 | 2023 | 270 | 0.220 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 74 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2009 | 1017 | 0.220 |
Why?
|
| Length of Stay | 4 | 2019 | 1291 | 0.220 |
Why?
|
| Arginine Vasopressin | 1 | 2004 | 25 | 0.210 |
Why?
|
| Kidney Diseases | 1 | 2008 | 467 | 0.210 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 2921 | 0.200 |
Why?
|
| Myocarditis | 3 | 2015 | 123 | 0.200 |
Why?
|
| Texas | 6 | 2016 | 3509 | 0.190 |
Why?
|
| Ambulatory Care | 1 | 2006 | 386 | 0.190 |
Why?
|
| Developmental Disabilities | 1 | 2007 | 715 | 0.190 |
Why?
|
| Chlorides | 1 | 2022 | 97 | 0.190 |
Why?
|
| Hypernatremia | 1 | 2023 | 32 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2016 | 1159 | 0.190 |
Why?
|
| Flecainide | 1 | 2002 | 20 | 0.180 |
Why?
|
| Sotalol | 1 | 2002 | 33 | 0.180 |
Why?
|
| Transferrin | 1 | 2021 | 46 | 0.180 |
Why?
|
| Hypotension | 2 | 2022 | 177 | 0.180 |
Why?
|
| Thrombosis | 2 | 2022 | 492 | 0.180 |
Why?
|
| Multivariate Analysis | 5 | 2019 | 1333 | 0.180 |
Why?
|
| Syndrome | 3 | 2009 | 1120 | 0.170 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2002 | 108 | 0.170 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 40 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 224 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 124 | 0.160 |
Why?
|
| North America | 1 | 2020 | 249 | 0.150 |
Why?
|
| Comorbidity | 3 | 2020 | 1518 | 0.150 |
Why?
|
| Patient Admission | 2 | 2014 | 164 | 0.150 |
Why?
|
| Age Factors | 5 | 2020 | 2749 | 0.150 |
Why?
|
| Postoperative Complications | 6 | 2016 | 2939 | 0.150 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 461 | 0.150 |
Why?
|
| Overweight | 1 | 2021 | 366 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 58 | 0.150 |
Why?
|
| Iron | 1 | 2021 | 295 | 0.150 |
Why?
|
| Age of Onset | 1 | 2020 | 605 | 0.140 |
Why?
|
| United States | 7 | 2021 | 11095 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 204 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2016 | 1116 | 0.140 |
Why?
|
| Heart Ventricles | 2 | 2019 | 745 | 0.130 |
Why?
|
| Walking | 1 | 2019 | 232 | 0.130 |
Why?
|
| American Heart Association | 1 | 2019 | 306 | 0.130 |
Why?
|
| Medical Records | 2 | 2016 | 176 | 0.130 |
Why?
|
| Echocardiography | 2 | 2018 | 1093 | 0.130 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2016 | 14 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 556 | 0.120 |
Why?
|
| Hypertrophy | 1 | 2016 | 100 | 0.120 |
Why?
|
| Hospital Charges | 1 | 2015 | 63 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.110 |
Why?
|
| Patient Discharge | 2 | 2020 | 457 | 0.110 |
Why?
|
| Disease Progression | 3 | 2016 | 2091 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2016 | 305 | 0.110 |
Why?
|
| Cardiac Catheterization | 3 | 2023 | 608 | 0.110 |
Why?
|
| Heart | 1 | 2019 | 641 | 0.110 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 24 | 0.110 |
Why?
|
| Graft Survival | 4 | 2021 | 449 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 1993 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 55 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 46 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2025 | 6133 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 899 | 0.100 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2014 | 42 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 1170 | 0.100 |
Why?
|
| Prevalence | 2 | 2018 | 2560 | 0.100 |
Why?
|
| Biomarkers | 2 | 2016 | 3115 | 0.100 |
Why?
|
| Stroke Volume | 2 | 2006 | 489 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2019 | 203 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1725 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1093 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 221 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2015 | 374 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1213 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 113 | 0.090 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 254 | 0.090 |
Why?
|
| Candidiasis | 1 | 2013 | 129 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2019 | 768 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1174 | 0.090 |
Why?
|
| Kidney | 2 | 2023 | 1246 | 0.080 |
Why?
|
| Colloids | 1 | 2009 | 16 | 0.080 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 329 | 0.080 |
Why?
|
| Isotonic Solutions | 1 | 2009 | 34 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2008 | 2160 | 0.080 |
Why?
|
| Natriuretic Agents | 1 | 2009 | 22 | 0.080 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 79 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2011 | 265 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2021 | 1638 | 0.070 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 503 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 555 | 0.070 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 121 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1018 | 0.070 |
Why?
|
| Consanguinity | 1 | 2007 | 118 | 0.070 |
Why?
|
| Cachexia | 1 | 2007 | 47 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2007 | 42 | 0.070 |
Why?
|
| Electromyography | 1 | 2007 | 136 | 0.060 |
Why?
|
| Patient Selection | 2 | 2010 | 686 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2006 | 26 | 0.060 |
Why?
|
| Systole | 1 | 2006 | 185 | 0.060 |
Why?
|
| Myocardium | 2 | 2008 | 827 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 5042 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2008 | 220 | 0.060 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2005 | 6 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 153 | 0.060 |
Why?
|
| Leukopenia | 1 | 2005 | 43 | 0.060 |
Why?
|
| Survival Rate | 2 | 2021 | 2025 | 0.060 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2005 | 73 | 0.060 |
Why?
|
| Tachycardia | 1 | 2005 | 72 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 675 | 0.060 |
Why?
|
| Cardiac Output, Low | 1 | 2005 | 60 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3254 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 137 | 0.060 |
Why?
|
| Outpatients | 1 | 2006 | 249 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2006 | 193 | 0.060 |
Why?
|
| Cause of Death | 1 | 2007 | 463 | 0.060 |
Why?
|
| Leukocytes | 1 | 2005 | 203 | 0.050 |
Why?
|
| Biopsy | 2 | 2023 | 1212 | 0.050 |
Why?
|
| Probability | 2 | 2019 | 293 | 0.050 |
Why?
|
| Aortic Coarctation | 1 | 2005 | 95 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 114 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2023 | 46 | 0.050 |
Why?
|
| Obesity | 2 | 2021 | 2310 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2005 | 306 | 0.050 |
Why?
|
| Dilatation | 1 | 2023 | 63 | 0.050 |
Why?
|
| Resuscitation | 1 | 2005 | 268 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2003 | 165 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 779 | 0.050 |
Why?
|
| Hirudins | 1 | 2022 | 35 | 0.050 |
Why?
|
| Infant Welfare | 1 | 2002 | 26 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 46 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2005 | 303 | 0.050 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2002 | 62 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2021 | 901 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 638 | 0.040 |
Why?
|
| Thinness | 1 | 2021 | 70 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2005 | 502 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2023 | 249 | 0.040 |
Why?
|
| Hemolysis | 1 | 2021 | 102 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1338 | 0.040 |
Why?
|
| Heparin | 1 | 2022 | 201 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 126 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 124 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 1278 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 465 | 0.040 |
Why?
|
| Quality of Life | 2 | 2020 | 2010 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1138 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 735 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1593 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 1387 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 229 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 716 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 555 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 474 | 0.030 |
Why?
|
| Public Health | 1 | 2019 | 267 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1081 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1714 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2019 | 461 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1811 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 482 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 541 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3555 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 2016 | 28 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1529 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 177 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 1453 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 668 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2016 | 360 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 235 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2013 | 10 | 0.030 |
Why?
|
| Phenotype | 1 | 2023 | 4296 | 0.030 |
Why?
|
| Heart Diseases | 2 | 2008 | 480 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 522 | 0.020 |
Why?
|
| Staphylococcus | 1 | 2013 | 68 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2014 | 177 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 1054 | 0.020 |
Why?
|
| Candida | 1 | 2013 | 81 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 471 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 762 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 74 | 0.020 |
Why?
|
| Forecasting | 1 | 2010 | 347 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 108 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2008 | 59 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 125 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2010 | 594 | 0.020 |
Why?
|
| Stroke | 1 | 2015 | 995 | 0.020 |
Why?
|
| Assisted Circulation | 1 | 2007 | 35 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 266 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 214 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 318 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 409 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 243 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 208 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2008 | 175 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 412 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 128 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Papillary Muscles | 1 | 2005 | 18 | 0.010 |
Why?
|
| Warfarin | 1 | 2006 | 106 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 412 | 0.010 |
Why?
|
| Aspirin | 1 | 2006 | 199 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2005 | 113 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2008 | 1077 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 733 | 0.010 |
Why?
|
| Exercise | 1 | 2009 | 832 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2013 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1620 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 235 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 791 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 854 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 960 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2007 | 853 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2363 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 27074 | 0.000 |
Why?
|